Neuronetics Anti-Depression Device Not Equivalent To Shock Therapy – Panel
This article was originally published in The Gray Sheet
Executive Summary
Neuronetics' NeuroStar transcranial magnetic stimulation system is not substantially equivalent to electroconvulsive "shock" therapy for treatment of major depressive disorder, FDA's Neurological Devices Panel concluded Jan. 26
You may also be interested in...
Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar
FDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis
Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar
FDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis
Neurotechnology Needs Better Outcome Measures, Diagnostics – VC Investors
The development and regulatory approval of new drugs and devices for treating diseases of the brain is hindered by the inadequacy of existing diagnostics and outcome measures, according to venture capitalists who spoke at a recent neurotech industry forum